Iqvia (NYSE:IQV) Releases FY20 Earnings Guidance

Iqvia (NYSE:IQV) issued an update on its FY20 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $7.15-7.35 for the period, compared to the Thomson Reuters consensus estimate of $7.22. The company issued revenue guidance of 11.775-12.000 billion, compared to the consensus revenue estimate of $11.84 billion.Iqvia also updated its FY 2020
Pre-Market guidance to 7.15-7.35 EPS.

Shares of NYSE IQV traded down $1.47 during trading on Friday, reaching $164.32. 2,962,308 shares of the stock were exchanged, compared to its average volume of 1,312,776. The business’s 50-day moving average price is $157.99 and its 200 day moving average price is $151.69. Iqvia has a twelve month low of $130.77 and a twelve month high of $169.14. The company has a quick ratio of 1.12, a current ratio of 1.12 and a debt-to-equity ratio of 1.85. The company has a market capitalization of $31.03 billion, a price-to-earnings ratio of 134.69, a price-to-earnings-growth ratio of 1.70 and a beta of 0.91.

Iqvia (NYSE:IQV) last posted its earnings results on Wednesday, February 12th. The medical research company reported $1.74 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. Iqvia had a net margin of 2.24% and a return on equity of 16.95%. The business had revenue of $2.90 billion for the quarter, compared to analysts’ expectations of $2.85 billion. During the same period in the previous year, the company posted $1.50 earnings per share. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. As a group, sell-side analysts expect that Iqvia will post 5.9 earnings per share for the current fiscal year.

IQV has been the topic of a number of recent research reports. Credit Suisse Group reissued a buy rating and set a $170.00 target price on shares of Iqvia in a research report on Friday, December 20th. Wells Fargo & Co initiated coverage on shares of Iqvia in a research report on Tuesday, January 7th. They set an overweight rating and a $180.00 target price on the stock. UBS Group boosted their target price on shares of Iqvia from $187.00 to $200.00 and gave the stock a buy rating in a research report on Thursday. Piper Sandler boosted their target price on shares of Iqvia from to in a research report on Thursday. Finally, ValuEngine cut shares of Iqvia from a hold rating to a sell rating in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $174.30.

In other Iqvia news, Director Michael J. Evanisko sold 6,250 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $160.08, for a total transaction of $1,000,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael R. Mcdonnell sold 12,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.07, for a total transaction of $1,860,840.00. Following the sale, the chief financial officer now owns 14,366 shares of the company’s stock, valued at approximately $2,227,735.62. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,000 shares of company stock valued at $5,830,215. Insiders own 6.00% of the company’s stock.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Story: New Google Finance Tool and Screening Stocks

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.